MIT scientists studied antigen expression patterns and T cell responses to understand why patients with heterogeneous tumors have poor responses to immune checkpoint blockade (ICB) therapies. They identified key antigen architectures that influence the immune system’s response to tumors. Using this insight, they developed an RNA-based therapeutic cancer vaccine that, when combined with ICB treatments, effectively controlled tumors in mouse models of lung cancer.
MIT researchers develop cancer vaccine to enhance immune checkpoint blockade response
Examining antigen architectures.
- Advertisement -
Explore more ..
High-fat diets and memory loss- A reversible story
Machine learning identifies early depression signals in facial patterns.
Why alcohol halts liver regeneration, even after quitting
New research links inflammation to faulty RNA processing
Breakthrough stool test could replace invasive colonoscopies
An artificial intelligence-based approach to diagnose colorectal cancer from the gut microbiota.
TRENDING
- Advertisement -